Propanc Biopharma, Inc. (PPCB) financial statements (2021 and earlier)

Company profile

Business Address 302/6 BUTLER STREET
CAMBERWELL, VICTORIA, 3124
State of Incorp. DE
Fiscal Year End June 30
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2020
TTM
6/30/2020
6/30/2019
6/30/2018
6/30/2017
6/30/2016
6/30/2015
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments0000000
Cash and cash equivalents0000000
Receivables000000 
Other undisclosed current assets  00001
Total current assets:0000001
Noncurrent Assets
Operating lease, right-of-use asset00
Property, plant and equipment0000000
Long-term investments and receivables  0000 
Due from related parties  0000 
Deposits noncurrent assets00     
Other undisclosed noncurrent assets     00
Total noncurrent assets:0000000
TOTAL ASSETS:0000001
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:1110000
Accounts payable1111000
Employee-related liabilities0000000
Other undisclosed accounts payable and accrued liabilities  (1)(1)(0)(0)0
Debt1225310
Deferred compensation liability0010111
Derivative instruments and hedges, liabilities    000
Due to related parties0000000
Other undisclosed current liabilities1111112
Total current liabilities:4447634
Noncurrent Liabilities
Total liabilities:4447634
Stockholders' equity
Stockholders' equity attributable to parent, including:(4)(4)(4)(7)(5)(3)(3)
Preferred stock0      
Common stock0000010
Treasury stock, value(0)(0)(0)(0)(0)  
Additional paid in capital52514638332717
Accumulated other comprehensive income (loss)1110(0)00
Accumulated deficit(57)(56)(51)(45)(38)(30)(21)
Other undisclosed stockholders' equity attributable to parent0000000
Total stockholders' equity:(4)(4)(4)(7)(5)(3)(3)
TOTAL LIABILITIES AND EQUITY:0000001

Income statement (P&L) ($ in millions)

12/31/2020
TTM
6/30/2020
6/30/2019
6/30/2018
6/30/2017
6/30/2016
6/30/2015
Gross profit:(0) (0)(0)(0)(0)(0)
Operating expenses(2)(3)(3)(4)(6)(7)(2)
Other undisclosed operating income0 00000
Operating loss:(2)(3)(3)(4)(6)(7)(2)
Nonoperating expense(0)(1)(4)(3)(2)(3)(2)
Foreign currency transaction loss, before tax  (1)   (0)
Other nonoperating expense(0)(1)(3)(3)(2)(3)(2)
Interest and debt expense(0)010(0)(1)(1)
Loss from continuing operations before equity method investments, income taxes:(2)(5)(5)(7)(8)(10)(5)
Other undisclosed loss from continuing operations before income taxes  (0)    
Loss from continuing operations before income taxes:(2)(5)(6)(7)(8)(10)(5)
Income tax benefit0000000
Net loss:(2)(5)(6)(7)(8)(10)(5)
Other undisclosed net income (loss) attributable to parent0(0)(0)(0)011
Net loss available to common stockholders, diluted:(2)(5)(6)(7)(8)(9)(3)

Comprehensive Income ($ in millions)

12/31/2020
TTM
6/30/2020
6/30/2019
6/30/2018
6/30/2017
6/30/2016
6/30/2015
Net loss:(2)(5)(6)(7)(8)(10)(5)
Comprehensive loss:(2)(5)(6)(7)(8)(10)(5)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent0010(0)12
Comprehensive loss, net of tax, attributable to parent:(2)(5)(5)(7)(8)(9)(3)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: